<DOC>
	<DOCNO>NCT00717366</DOCNO>
	<brief_summary>This sequential study ass efficacy safety multiple dose intravenous Mircera , determine optimum start dose maintenance treatment anemia child chronic kidney disease hemodialysis . Pediatric patient remain epoetin alfa , epoetin beta darbepoetin alfa screening period , receive intravenous Mircera monthly , start dose relate previous weekly epoetin darbepoetin alfa dose . Depending response achieve , another group may select receive high low dose . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Intravenous Mircera Treatment Anemia Pediatric Patients Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>write informed consent parent/legal guardian and/or assent child appropriate require national legislation child age 517 year ( Russia : 1217 year ) clinically stable chronic renal anemia ; hemodialysis &gt; =8 week ; intravenous stable maintenance epoetin alfa , epoetin beta darbepoetin alfa &gt; = 8 week screen weekly dose change &gt; /=25 % ( increase decrease ) 2 week screen . overt gastrointestinal bleeding , bleed episode necessitate transfusion within 8 week screen ; red blood cell ( RBC ) transfusion within 8 week screen ; active malignant disease ; pure red cell aplasia ( PRCA ) history PRCA ; pregnant lactating ; sexually active patient : willing use reliable contraception .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>